U.S. NeuroSurgical Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021
November 19, 2021 at 04:02 pm EST
Share
U.S. NeuroSurgical Holdings, Inc. reported earnings results for the third quarter and nine months ended September 30, 2021. For the third quarter, the company reported net loss was USD 0.344 million compared to net income of USD 0.164 million a year ago. Basic loss per share from continuing operations was USD 0.04 compared to basic earnings per share from continuing operations of USD 0.02 a year ago.
For the nine months, sales was USD 1.06 million compared to USD 2.01 million a year ago. Net loss was USD 0.378 million compared to net income of USD 0.384 million a year ago. Basic loss per share from continuing operations was USD 0.05 compared to basic earnings per share from continuing operations of USD 0.05 a year ago.
U.S. NeuroSurgical Holdings, Inc., through its wholly-owned subsidiaries, holds interests in radiological treatment facilities. The Company owns and operates stereotactic radiosurgery centers, utilizing gamma knife technology. It owns, or holds interests in, the gamma knife and radiation treatment centers, and charges the hospital or medical facility, where the unit is housed and maintained, based on utilization. It is also focused on developing cancer centers featuring radiation therapy. These centers utilize linear accelerators with Intensity Modulated Radiation Therapy and Image Guided Radiation Therapy capabilities. It is focused on launching and development of Medicare advantage plans for seniors by its subsidiaries, Elite Health Plan and Elite Health Plan of Nevada, Inc. Medicare is the federal health insurance program for people ages 65 and over, to cover people under 65 with certain disabilities and people with end-stage renal disease requiring dialysis or kidney transplant.
U.S. NEUROSURGICAL HOLDINGS, INC. 
